Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

[ 18 F]-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) is considered
a valuable tool in the diagnosis and staging of cancer. In addition, it seems promising as a …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

… EF Smit was the pulmonologist and principal investigator, and developed the study protocol.
JHAM van den Bergh, AJM Schreurs, RALM Stallaert, and JC van Mourik were coprincipal …

Background BRAF V600E mutation occurs in 1–2% of lung adenocarcinomas and acts as
an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial …

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic
and local responses to tumor growth, thereby altering their RNA profile. We determined the …

Background Induction chemotherapy before surgical resection increases survival compared
with surgical resection alone in patients with stage IIIA-N2 non–small-cell lung cancer (…

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …